casimiropt / Shutterstock.com
7 May 2019Big Pharma
English High Court invalidates Allergan glaucoma patent
One of Allergan’s patents has been invalidated after it was challenged by UK-based pharmaceutical companies Accord Healthcare and Aspire Pharma.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
20 March 2019 Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.
Big Pharma
18 March 2019 A district court must revisit its decision that one of Allergan’s patents is valid and was not infringed by a competitor.
Editor's picks
Editor's picks
Big Pharma
20 March 2019 Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.
Big Pharma
18 March 2019 A district court must revisit its decision that one of Allergan’s patents is valid and was not infringed by a competitor.
Big Pharma
20 March 2019 Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.
Big Pharma
18 March 2019 A district court must revisit its decision that one of Allergan’s patents is valid and was not infringed by a competitor.